Can-Fite BioPharma Ltd. (CANF) Form 6-K — Sep 3, 2026
Can-Fite BioPharma entered into an inducement offer letter on September 2, 2026, under which a holder agreed to exercise for cash existing warrants covering 1,591,738 ADSs at a reduced price of $2.50 per ADS, down from the original $5.00 exercise price, for expected gross proceeds of approximately $4.0 million. In consideration, the company issued new unregistered warrants to purchase up to 3,183,476 ADSs (200% warrant coverage) at $2.50 per ADS with a 24-month term, and engaged H.C. Wainwright & Co. as exclusive placement agent for a 7.0% cash fee, a 1.0% management fee, $75,000 in expenses, and warrants for 111,422 ADSs at $3.125 per ADS.
Key figures
- Gross Proceeds
- 4000000
- Offering Price
- 2.5
- Cash fee pct
- 7
- New warrant term
- 24 months from resale registration statement effectiveness
- New warrants ads
- 3183476
- Warrant coverage
- 200% of existing warrants exercised
- Clearing fees usd
- 15950
- Management fee pct
- 1
- Issuance lockup days
- 30
- Ads to ordinary share ratio
- 1 ADS = 2 ordinary shares
- Non accountable expenses usd
- 75000
- Placement agent warrants ads
- 111422
- Existing warrants ads exercised
- 1591738
- Original exercise price per ads
- 5
- New warrant exercise price per ads
- 2.5
- Variable rate transaction restriction
- 1 year
- Resale registration effective within days
- 90
- Placement agent warrant exercise price per ads
- 3.125
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.